BR112023020341A2 - Anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcma - Google Patents
Anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcmaInfo
- Publication number
- BR112023020341A2 BR112023020341A2 BR112023020341A BR112023020341A BR112023020341A2 BR 112023020341 A2 BR112023020341 A2 BR 112023020341A2 BR 112023020341 A BR112023020341 A BR 112023020341A BR 112023020341 A BR112023020341 A BR 112023020341A BR 112023020341 A2 BR112023020341 A2 BR 112023020341A2
- Authority
- BR
- Brazil
- Prior art keywords
- bcma
- treating
- pharmaceutical composition
- disease related
- antibody
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 3
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 title 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 title 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 title 1
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Abstract
anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcma. é fornecido um anticorpo multiespecífico direcionado ao bcma. são especificamente fornecidos um anticorpo multiespecífico, um ácido nucleico que codifica o mesmo, um vetor compreendendo o ácido nucleico, uma célula compreendendo o vetor e uma composição farmacêutica compreendendo o mesmo. é ainda fornecida a sua utilização para o tratamento de um sujeito com uma doença relacionada com a expressão de bcma.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110405638 | 2021-04-15 | ||
PCT/CN2022/086842 WO2022218380A1 (zh) | 2021-04-15 | 2022-04-14 | 靶向bcma的多特异性抗体 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112023020341A2 true BR112023020341A2 (pt) | 2024-02-06 |
Family
ID=83640152
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112023020341A BR112023020341A2 (pt) | 2021-04-15 | 2022-04-14 | Anticorpo multiespecífico, composição farmacêutica, método para tratar uma doença relacionada à expressão de bcma e anticorpo de ligação a bcma |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP4324853A1 (pt) |
JP (1) | JP2024516098A (pt) |
KR (1) | KR20230170721A (pt) |
CN (1) | CN117062840A (pt) |
AU (1) | AU2022256638A1 (pt) |
BR (1) | BR112023020341A2 (pt) |
CA (1) | CA3214012A1 (pt) |
IL (1) | IL307308A (pt) |
TW (1) | TW202304963A (pt) |
WO (1) | WO2022218380A1 (pt) |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105384825B (zh) | 2015-08-11 | 2018-06-01 | 南京传奇生物科技有限公司 | 一种基于单域抗体的双特异性嵌合抗原受体及其应用 |
MX2019004621A (es) | 2016-11-02 | 2019-11-28 | Engmab Sarl | Anticuerpo biespecifico contra bcma y cd3 y un farmaco inmunologico para uso combinado en el tratamiento del mieloma multiple. |
KR20200018498A (ko) * | 2017-06-20 | 2020-02-19 | 테네오바이오, 인코포레이티드 | 항-bcma 중쇄-단독 항체 |
CA3095093A1 (en) | 2018-04-05 | 2019-10-10 | Novartis Ag | Trispecific binding molecules against cancers and uses thereof |
AU2019370339A1 (en) * | 2018-11-01 | 2021-06-10 | Shandong New Time Pharmaceutical Co., Ltd. | Bispecific antibody and use thereof |
CN110551221B (zh) * | 2019-07-02 | 2021-03-05 | 广州爱思迈生物医药科技有限公司 | 一种双特异性抗体及其制备方法与应用 |
WO2022037528A1 (zh) * | 2020-08-20 | 2022-02-24 | 正大天晴药业集团股份有限公司 | 结合bcma的单可变结构域及抗原结合分子 |
CN112794916B (zh) * | 2021-04-08 | 2021-08-10 | 正大天晴药业集团南京顺欣制药有限公司 | 三特异性抗原结合构建体及构建方法和应用 |
-
2022
- 2022-04-14 CN CN202280022841.5A patent/CN117062840A/zh active Pending
- 2022-04-14 KR KR1020237038699A patent/KR20230170721A/ko unknown
- 2022-04-14 CA CA3214012A patent/CA3214012A1/en active Pending
- 2022-04-14 WO PCT/CN2022/086842 patent/WO2022218380A1/zh active Application Filing
- 2022-04-14 EP EP22787602.6A patent/EP4324853A1/en active Pending
- 2022-04-14 AU AU2022256638A patent/AU2022256638A1/en active Pending
- 2022-04-14 BR BR112023020341A patent/BR112023020341A2/pt unknown
- 2022-04-14 IL IL307308A patent/IL307308A/en unknown
- 2022-04-14 TW TW111114188A patent/TW202304963A/zh unknown
- 2022-04-14 JP JP2023561864A patent/JP2024516098A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
AU2022256638A1 (en) | 2023-11-09 |
IL307308A (en) | 2023-11-01 |
TW202304963A (zh) | 2023-02-01 |
WO2022218380A1 (zh) | 2022-10-20 |
CA3214012A1 (en) | 2022-10-20 |
CN117062840A (zh) | 2023-11-14 |
EP4324853A1 (en) | 2024-02-21 |
KR20230170721A (ko) | 2023-12-19 |
JP2024516098A (ja) | 2024-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017013599A2 (pt) | composição farmacêutica, e, método para prevenir, tratar ou melhorar um ou mais sintomas de um tumor maligno associado à mutação de kras. | |
BR112019000512A2 (pt) | anticorpo, ácido nucleico, vetor de expressão, célula hospedeira, composição, métodos de tratamento de uma doença, para produzir um anticorpo biespecífico e para detectar se a reticulação entre as células que expressam cd40 e cd137 ocorre em uma amostra, uso de um anticorpo multiespecífico, e, kit | |
CL2016003324A1 (es) | Construcciones de anticuerpos multiespecificos. | |
BR112018001995A2 (pt) | moléculas de ácido nucleico artificial | |
BR112015008708A2 (pt) | composição para clivagem de dna alvo compreendendo um rna guia específico para o dna alvo e ácido nucleico que codifica proteína cas ou proteína cas e uso da mesma | |
BR112016030424A2 (pt) | construções de anticorpo multiespecíficas | |
BR112015014372A2 (pt) | inibidores de autotaxina | |
CL2020000937A1 (es) | Anticuerpo multiespecífico. | |
BR112017018728A2 (pt) | sistema de vetor para expressar a sequência de codificação de um gene de interesse em uma célula, célula hospedeira, composição farmacêutica, método para tratar e/ou prevenir uma patologia ou doença, uso de uma sequência de nucleotídeo de um sinal de degradação em um sistema de vetor e método para diminuir a expressão de uma proteína na forma truncada | |
BR112021022335A2 (pt) | Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer | |
BR112019005129A2 (pt) | anticorpos anti-pd-1 | |
AR074124A1 (es) | Composiciones y metodos para inhibir la expresion de genes del factor vii | |
BR112018073298A2 (pt) | cápsula, suspensão de cápsula, mistura, uso das cápsulas e método para reduzir a nitrificação | |
BR112012009432A2 (pt) | anticorpo anti-hsv | |
BR112021022171A2 (pt) | Anticorpo para tigit, seu uso e método para produzir o mesmo | |
EA202091318A1 (ru) | Препарат, содержащий аденовирус группы b | |
BR112015001521A2 (pt) | previsão de resposta ao tratamento para inibidor jak/stat | |
BR112013017363A2 (pt) | biblioteca de alphabody de cadeia única, mistura de bibliotecas de alphabody, ácido nucleico ou biblioteca de vetor, biblioteca de células hospedeiras, uso de uma biblioteca de alphabody de cadeia única, método para a produção de uma biblioteca de alphabody de cadeia única, método para a produção de um ou mais polipeptídeos de alphabody de cadeia única, polipeptíceo de alphabody de cadeia única, ácido nucleico, vetor e célula hospedeira | |
BR112019024566A2 (pt) | inibidores de pirazol magl | |
BR112022008365A2 (pt) | Inibidores de cd73 | |
BR112023000826A2 (pt) | Anticorpo anti-ctla-4 e uso do mesmo | |
BR112022004972A2 (pt) | Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso | |
BR112022000628A2 (pt) | Anticorpos anti-tigit e aplicação dos mesmos | |
BR112022007907A2 (pt) | Método de produção de l-metionina, micro-organismo que produz l-metionina, composição para produzir l-metionina, e, uso de um micro-organismo | |
BR112022006476A2 (pt) | Oligonucleotídeos com análogos de nucleosídeos |